Strategic Development of Neural Stem & Progenitor Cell Products
|発行||BIOINFORMANT WORLDWIDE, LLC||商品コード||227599|
|出版日||ページ情報||英文 113 Pages
|神経幹細胞・前駆細胞製品の戦略的開発 Strategic Development of Neural Stem & Progenitor Cell Products|
|出版日: 2012年01月04日||ページ情報: 英文 113 Pages||
Neurogenesis is the process by which neurons are created. This process is most active during pre-natal development when neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types include neurons, astrocytes, and oligodendrocytes. Neural progenitor cells (NPCs) are the progeny of stem cell division that normally undergo a limited number of replication cycles in vivo.
The terms neuronal and neural also need to be defined. Technically speaking, “neuronal” means “pertaining to neurons," and “neural” means “pertaining to nerves, which are the cordlike bundles of fibers made up of neurons.” Since both terms ultimately are descriptive of neurons, the scientific community uses the terms "neuronal" and "neural" interchangeably. The complexity of this issue is explored from a strategic perspective within this report.
In particular, when naming products, companies are advised to use the term “neural” rather than “neuronal,” both in reference to stem cells and progenitor cells, in order to best position products within the marketplace. Also of interest is that when “stem cell” versus “progenitor cell” publications are compared, neural/neuronal “stem cell” publication rates continue to outpace neural/neuronal “progenitor cell” publications by over 200% over a trailing two-year period.
In summary, an understanding of neural stem cell language and terminology can substantially improve product naming, strategic positioning, and the effectiveness of marketing communications. These subtleties as explored in detail within the context of this industry report.
In addition, the report focuses on: recent advances in neural stem cell research applications; research priorities by market segment; opportunities for profitable product and technology development; the competitive environment for NSC products; detailed market size analysis; market trends and metrics; five-year projections; and the needs and decision-making of NSC scientists.
In 1992, Reynolds and Weiss were the first to isolate neural stem cells from the striatal tissue of adult mice brain tissue, including the subventricular zone, which is a neurogenic area. Since then, neural progenitor and stem cells have been isolated from various areas of the adult brain, including non-neurogenic areas like the spinal cord, and from other species, including humans. During the development of the nervous system, neural progenitor cells can either stay in the pool of proliferating undifferentiated cells or exit the cell cycle and differentiate. The past twenty years have seen great advances in neural stem cell research and applications. Researchers have isolated NSCs, which have demonstrated pluripotency and the ability to differentiate into many different immune system cell types. In addition, NSCs can be regulated both in vitro and in vivo, which represent different commercial product opportunities. Neural stem cells have also become of profound interest to the research community due to their potential to be used in drug discovery and delivery applications, as well as for tools of neural toxicology assessment. NSC transplantation also represents a ground-breaking approach for treating a range of chronic neurological diseases and acute CNS injuries, including Parkinson's, Alzheimer's and spinal cord injury, among other conditions.
Furthermore, neural stem and progenitor cells offer the potential to safely carry out pharmacology assessment for drugs designed to impact brain function or physiology. As tests on human cells become increasingly feasible, the potential grows for companies to develop disease-specific cell assays by producing recombinant stem cell lines expressing a therapeutic target. As novel drug delivery agents, neural stem cells also show promise in killing gliomas and other cancers. Finally, viable therapies for treating disease through neural stem cell transplantation are also on the horizon for forward-thinking researchers.
To facilitate research resulting from these advances, a large and diverse market has emerged for neural stem cell products, platforms, and technologies. In total, the neural stem cell product marketplace is comprised of the global sales of these items. One thriving component of this marketplace is the segment of companies that sell NSC research products to scientists.
Termed “research supply companies” or “research product vendors,” large companies selling neural stem cell research products include EMD Millipore, Life Technologies, Thermo Fisher Scientific, and STEMCELL Technologies, as well as more than 40 other suppliers that range in size from multinational corporations to small specialty companies. Together, these research supply companies represent a substantial annual percentage of NSC product sales. Each of these industry participants are identified within the context of this report. As of 2013, EMD Millipore, known as Merck Millipore outside of the United States and Canada, is the leader in neural stem cell product development for the scientific community. A Canadian company, STEMCELL Technologies, is a close second in the area of NSC product development for scientists.
Within this report, profitable opportunities for NSC research product development are revealed. Specifically, competitors looking to enter the NSC research products marketplace would do well to focus their energy on the areas considered highest priority by the scientific community, specifically cell-based therapies and standardized neurotoxicity assays. Due to recent legislative initiatives, interest in the latter is expected to increase significantly in the next several years. Furthermore, companies looking to enter the NSC product market could also focus their efforts on areas in which available products are not yet optimized for use with rat or mouse neural stem cells. Or, research supply companies could choose to focus product development on areas where human neural stem cell products are not yet available, although there would be some necessary work-around due to patent restrictions. Companies could also develop products for which there is little market competition, such as hESC-derived neural progenitors, kits for analysis of NSC differentiated progeny, NSC blotting and nucleofaction kits, and PCR arrays. Finally, companies could choose to explore varied sources from which to potentially derive neural stem cell products, such as human umbilical cord blood and derivatives of neural rosette cell lines.
In addition, pharmaceutical companies also have intense interest in neural stem cell product development. Because of their plasticity, ability to develop into the main phenotypes of the nervous system, and unlimited capacity for self-renewal, NSCs have been proposed for use in a variety of pharmaceutical applications, including:
While development of therapies that involve embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs) continue to expand, development of neural stem cell therapies has been more substantially affected by barriers to entry, including patent restrictions, the dominance of current competitors, and the complexity of neural stem cell applications. Nonetheless, within the area of NSC therapy development, there are currently three dominant competitors, which are Neural Stem, NeuroNova AB, and NeuroGeneration. In addition to those companies, there are also more than a dozen other companies actively developing NSC therapies for use in the treatment of human injury and disease.
For this reason, development of NSC products by the pharmaceutical sector also represents a thriving segment of the global NSC product marketplace. Of particular interest to this community is the potential for use of NSCs to heal tissues that have a naturally limited capacity for renewal, such human brain and spinal cord tissues.
Furthermore, within the pharmaceutical sector, development of new drugs is extremely costly and the success rate of bringing new compounds to the market is unpredictable. Therefore, it is crucial that pharmaceutical companies minimize late-stage product failures, such as suboptimal pharmacokinetic properties or unexpected neurotoxicity effects, that can can arise when candidate drugs enter the clinical testing stages. To achieve this, it would be highly desirable to test candidate drugs using in vitro assays of high human relevance as early as possible. Because NSCs have the potential to differentiate into nearly all of the main phenotypes of the nervous system, they represent an ideal cell type from which to design such neural screening assays.
In summary, the unifying factor within the NSC product marketplace is that all companies involved need to understand market forces, trends, metrics, and financials, in order to out-compete the competition and make more profitable decisions. Producing NSC products can involve complicated and confusing decisions, but it doesn't have to.
Claim this report to reveal the current and future needs of the NSC marketplace, so you can focus your marketing efforts on the most profitable products, in the most promising research areas, and within the most lucrative domestic and international markets. Your competitors would prefer you didn't buy this report. But when you do, you'll be gaining invaluable stem cell market insights to help you control and dominate this market.
To profit from this rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial NSC product trends. Claim this must-read industry report to optimally position yourself to sell NSC products.